Establishment of acquired radioresistant cells to fractionated radiation from hTERT-immortalized normal human epithelial cell
Radiation Protection Dosimetry · 2024
DOI: 10.1093/rpd/ncae118 ↗Kurz gefasst
Fachartikel in der Zeitschrift Radiation Protection Dosimetry, 2024. Verfasst von Masatoshi Suzuki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Radiological Disasters and Medical Science, International Research Institute of Disaster Science, Tohoku University, 519-1176 Aramaki-a…. Hauptthemen laut MEDLINE: Epithelial Cells, Radiation Tolerance, Telomerase, Dose Fractionation, Radiation. Die Arbeit nennt 11 Literaturangaben. Gefördert von: Network-type Joint Usage/Research Center for Radiation Disaster Medical Science, QST Research Collaboration for Fusion DEMO, NIFS Collaboration Research program.
Abstract (Originalsprache)
Senescence-like growth arrest (SLGA), which is a radiation-induced cell death pathway, is induced in immortalized normal human epithelial cell (hTERT-RPE1) by the daily fractionated X-irradiation with 1.5 Gy within 30 times. We here demonstrate that pre-treatment induces acquired radioresistance (ARR) that can survive from the lethal fractionated radiation. The parent cells were daily fractionated with 1.5 Gy for 5 d and then incubated for 7 d without fractionated radiation. After this, the daily fractionated radiation with 1.5 Gy was restarted. A small population of surviving cells appeared after 30 times of the daily fractionated radiation was completed and they were continuously growing up to 120 times of the daily fractionated radiation (RPE1–1.5Fr). We confirmed a higher basal expression level of p53, which functions in the activation of the SLGA pathway but fails to further accumulate after 1.5 Gy of single irradiation in RPE1–1.5Fr. It is the first report to induce ARR phenotype for fractionated radiation in normal human cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Radiological Disasters and Medical Science, International Research Institute of Disaster Science, Tohoku University, 519-1176 Aramaki-aza-Aoba, Aoba-ku, Sendai 980-0845, Japan.
- Radiological Technology, Health Science, Graduate School of Medicine, Tohoku University, 2-1 Seiryomachi, Aoba-ku, Sendai 980-8575, Japan.
- Department of Radiation Medical Sciences, Nagasaki University Atomic Bomb Disease Institute, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.
- Radiochemistry, Graduate School of Science, Tohoku University, 6-3 Aramaki-aza-Aoba, Aoba-ku, Sendai 980-8578, Japan.
- Department of Risk Analysis and Biodosimetry, Institute of Radiation Emergency Medicine, Hirosaki University, 66-1 Hon-cho, Hirosaki, Aomori 036-8564, Japan.
- Pathology Informatics Team, RIKEN Center for Advance Intelligence Project, 1-4-1 Nihonbashi Chuo-ku, Tokyo 103-0027, Japan.
ORCID-Profile: Masatoshi Suzuki, Rio Isobe, Tomisato Miura
Förderung
- Network-type Joint Usage/Research Center for Radiation Disaster Medical Science
- QST Research Collaboration for Fusion DEMO
- NIFS Collaboration Research program
- JSPS KAKENHI
Zitieren
APA
Suzuki, M., Isobe, R., Sato, T., Ishikawa, R., Suzuki, K., Kino, Y., Miura, T., Inaba, Y., Chida, K., & Fukumoto, M. (2024). Establishment of acquired radioresistant cells to fractionated radiation from hTERT-immortalized normal human epithelial cell. Radiation Protection Dosimetry. https://doi.org/10.1093/rpd/ncae118
Vancouver
Suzuki M, Isobe R, Sato T, Ishikawa R, Suzuki K, Kino Y, et al. Establishment of acquired radioresistant cells to fractionated radiation from hTERT-immortalized normal human epithelial cell. Radiation Protection Dosimetry. 2024. doi:10.1093/rpd/ncae118
BibTeX
@article{Suzuki2024,
author = {Suzuki, Masatoshi and Isobe, Rio and Sato, Taku and Ishikawa, Ryoya and Suzuki, Keiji and Kino, Yasushi and Miura, Tomisato and Inaba, Yohei and Chida, Koichi and Fukumoto, Manabu},
title = {Establishment of acquired radioresistant cells to fractionated radiation from hTERT-immortalized normal human epithelial cell},
journal = {Radiation Protection Dosimetry},
year = {2024},
doi = {10.1093/rpd/ncae118}
}
EUVIMED